Press "Enter" to skip to content

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

Patients with type 2 diabetics and either heart disease or at high risk for heart problems who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8% compared with 4.8% for placebo, successfully demonstrating non-inferiority.

Original source: